1[1]Luzzatto G,Schafer AL.The prethrombotic state in cancer[J].Semin Oncol,1990,17(2):147-159.
2[2]Golhaber SE.Epidemiology of pulmonary embolism and deep vein-thrombosis[A].IN:Bloom AL,Forbes CD,Thomas DP,ets.Haemostasis and thrombosis[M].London:Churchill,1994:1327-1342.
3[3]Weitz JI.Low molecular-weight heparins[J]. N Engl J Med,1997,337(10):688-698.
4[4]Stevens MCG,Mahler H,Parkes S.The health of adults survivors of cancer in childhood[J]. Eur J Cancer,1998,34(5):694-698.
5[5]Naschitz JE,Yeshurun D,Lev LM.Thromboembolism in cancer:changing trends[J].Cancer,1993,71(4):1384-1390.
6[6]Gordon B,Haire W,Kessinger,A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma[J].Bone Marrow Transplant,1991,8(6):497-502.
7[7]Moore FD,Osteen RT,Karp DD,et al.Anticoagulants,vennous thromboembolism,and the cancer patient[J].Arch Surg,1981,116(4):405-407.
8[8]Hull RD,Delmore T,Carter C,et al.Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis[J].N Engl J Med,1982,306(1):189-194.
